论文部分内容阅读
目的:探讨急诊经皮冠状动脉介入治疗术(PCI)中应用国产血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班对糖尿病并ST段抬高急性心肌梗死(AMI)患者预后的影响。方法:97例首发ST段抬高AMI且有糖尿病病史并接受急诊PCI治疗成功的患者,按术中应用替罗非班与否,分为替罗非班治疗组(观察组,n=47);常规治疗组(对照组,n=50)。测量2组术后左心室舒张期末容积指数(LVEDVI)、左心室收缩期末容积指数(LVES-VI)、左心室射血分数(LVEF);观察术后梗死后心绞痛、心力衰竭、心源性休克及住院期间病死率发生情况。结果:与对照组比较,观察组术后3个月左心室容积减小,LVEDVI[(65.2±5.4)ml/m2:(68.3±5.7)ml/m2,P<0.05],LVESVI[(31.5±4.2)ml/m2:(35.6±3.7)ml/m2,P<0.05],LVEF升高[(0.52±0.04)%:(0.48±0.03)%,P<0.05];梗死后心绞痛、心力衰竭、心源性休克发生率及住院期间病死率明显减低,比较差异有统计学意义(P<0.05)。结论:急诊经皮冠状动脉介入治疗术中应用替罗非班可改善糖尿病并ST段抬高急性心肌梗死患者临床及预后。
Objective: To investigate the effect of domestic platelet glycoprotein Ⅱb / Ⅲa receptor antagonist tirofiban on the prognosis of patients with diabetes mellitus and ST segment elevation acute myocardial infarction (AMI) during emergency percutaneous coronary intervention (PCI). Methods: Ninety-seven patients with initial ST-segment elevation AMI who had a history of diabetes mellitus and received emergency PCI were divided into tirofiban-treated group (n = 47) ; Conventional treatment group (control group, n = 50). Left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index (LVES-VI) and left ventricular ejection fraction (LVEF) were measured in two groups. Postoperative angina pectoris, heart failure, cardiogenic shock And mortality during hospitalization. Results: Compared with the control group, the left ventricular volume decreased at 3 months after operation in the observation group, with LVEDVI [(65.2 ± 5.4) ml / m 2: (68.3 ± 5.7) ml / m 2, P < (0.52 ± 0.04)% (± 0.48 ± 0.03)%, P <0.05]; Angina pectoris, heart failure, heart failure, The incidence of cardiogenic shock and hospital mortality significantly reduced, the difference was statistically significant (P <0.05). Conclusion: The application of tirofiban in emergency percutaneous coronary intervention improves the clinical and prognosis of diabetic patients with ST segment elevation acute myocardial infarction.